Your session is about to expire
← Back to Search
DCVC H1 HA mRNA Vaccine for Flu
Study Summary
This trial tests safety and effectiveness of a new intramuscular mRNA vaccine for influenza A/California/07/2009 (H1N1) in 18-49 yr olds. Primary goal is to assess safety, secondary is to compare antibody responses to a standard dose of inactivated vaccine.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have had Guillain-Barré Syndrome in the past.I have a history of heart inflammation.I have or recently had cancer in my blood.I have a long-term liver condition.I have been sick or had a fever in the last 3 days.I can follow the study's procedures and attend all visits.I have used steroids in the past month.I agree not to donate sperm and to use contraception for 90 days after my last vaccine dose.I have an immune system condition or autoimmune disease.I have been immunosuppressed due to treatment in the last 6 months.I haven't had cancer treatment or radiation in the last 3 years.I have used high-dose inhaled or nebulized steroids in the last 30 days.I had the flu within the last 3 months.I have not donated blood or blood products in the last 30 days.I am using or willing to use birth control or practice true abstinence.I do not have any undiagnosed or untreated ongoing health issues.I have not taken part in any clinical trials or received experimental treatments in the last 60 days.I am in good health without significant medical or psychiatric conditions.I cannot become pregnant because I am post-menopausal or have been surgically sterilized.I have received the flu vaccine in the last 90 days.I am a male participant and do not need to change my sexual or sperm donation practices for this study.I've been close to someone with COVID-19 or the flu recently.I have HIV, hepatitis B, or hepatitis C.I am a man or a woman not pregnant or breastfeeding, aged 18-49.I have received blood products or immunoglobulin within the last 3 months.I have not been hospitalized for mental health issues, attempted suicide, or been confined for being a danger to myself or others in the last 5 years.I am receiving treatment for a blood clotting disorder.My BMI is between 18 and 35, and I weigh at least 110 lbs.
- Group 1: Arm 1
- Group 2: Arm 2
- Group 3: Arm 4
- Group 4: Arm 5
- Group 5: Arm 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks are associated with the first arm of this trial?
"Without a significant amount of data to assess efficacy or safety, our team has appraised Arm 1's risk with a score of one."
What are the prerequisites for enrolling in this trial?
"To meet the criteria for this clinical trial, participants must present with influenza and be aged between 18 and 49. The total number of eligible patients is limited to 50 individuals."
Does this clinical investigation allow participants aged 25 and above?
"This clinical trial is only available to patients between the ages of 18 and 49. Those younger than 18, as well as those over 65, can explore 39 or 79 different medical studies respectively."
Is there still an opportunity to participate in this experiment?
"The information found on clinicaltrials.gov reveals that this specific medical trial is not currently recruiting for patients. This research project was initially posted to the website on July 20th, 2023 and last updated on July 6th,2023. Despite being inactive at present, there are many alternate trials which have open enrollment opportunities available now."
Share this study with friends
Copy Link
Messenger